Collavant® n2 - Clinical Research Data Summary
Collavant® n2 Native Type II Collagen
Collavant® n2 is a clinically studied ingredient used in the following Silver Fern™ Brand product:
- Joint Complex – https://www.silverfernbrand.com/products/joint-complex
Introduction
Collavant® n2 is a native (undenatured) type II collagen derived from chicken sternum that has been studied for its role in supporting joint comfort, mobility, and cartilage health. Unlike hydrolyzed collagen, which primarily provides structural amino acids used in connective tissue formation, native type II collagen functions through a mechanism known as oral tolerance and is effective at very low doses, typically 40 mg per day. Through this process, small amounts of dietary collagen interact with immune cells in the gut-associated lymphoid tissue, helping support balanced immune responses associated with normal joint tissue and cartilage metabolism.
Human clinical research — including randomized controlled trials in healthy, physically active individuals and populations experiencing joint discomfort — has evaluated the effects of daily supplementation with native type II collagen. These studies have reported improvements in joint comfort, physical function, walking capacity, and quality-of-life measures related to joint health. Preclinical research exploring the oral tolerance mechanism has also examined how orally administered type II collagen interacts with immune signaling pathways associated with joint tissues. These findings help explain why native type II collagen has been evaluated in human studies at low daily doses and suggest a role in supporting healthy cartilage metabolism and joint resilience during periods of physical stress.*
These are the studies for Collavant® n2. Below, we provided a summary of each key data for each study, along with a link to the complete clinical research.
- Summary of Study 1 – Full Study: https://pubmed.ncbi.nlm.nih.gov/36562843/
- Summary of Study 2 – Full Study: https://pubmed.ncbi.nlm.nih.gov/35612617/
- Summary of Study 3 – Full Study: https://www.ijoro.org/index.php/ijoro/article/view/1840
- Summary of Study 4 – Full Study: https://pubmed.ncbi.nlm.nih.gov/27551171/
- Summary of Study 5 – Full Study: https://pubmed.ncbi.nlm.nih.gov/19384621/
Ingredient Manufacturer Link: https://www.bioiberica.com/en/products/human-health/collavantr-n2
Study 1 Summary
Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/36562843/
Efficacy and Safety of Native Type II Collagen in Modulating Knee Osteoarthritis Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial
J Exp Orthop. 2022;9(1):123. doi:10.1186/s40634-022-00559-8. PMID: 36562843.
This randomized, double-blind, placebo-controlled clinical trial evaluated the effects of 40 mg/day native (undenatured) type II collagen (Collavant® n2) in 74 healthy adults experiencing joint discomfort following intensive physical activity. Participants supplemented daily for 180 days, and researchers assessed recovery time from exercise-induced knee discomfort, joint function, and quality of life using validated outcome measures including the Knee Injury and Osteoarthritis Outcome Score (KOOS).
Study Design Highlights
- Study design: Randomized, double-blind, placebo-controlled clinical trial
- Participants: 74 healthy adults with exercise-related joint discomfort
- Dose: 40 mg/day native type II collagen
- Duration: 180 days (6 months)
- Primary outcomes: Recovery time from exercise-induced knee discomfort; KOOS scores for pain, symptoms, daily activities, sport and recreation function, and quality of life
Key Findings (What the Study Showed)
- Improved recovery time from exercise-induced knee discomfort vs. placebo
- Significant improvements in KOOS pain scores
- Significant improvements in KOOS symptom scores
- Significant improvements in KOOS daily activities scores
- Significant improvements in KOOS sport and recreation function scores
- Improved joint comfort and physical performance following physical stress
Benefits of Collavant® n2 Demonstrated by This Study
Based directly on the clinical outcomes, Collavant® n2 was shown to:
✓ Support improved recovery from exercise-related knee discomfort
✓ Support improvements in joint comfort (KOOS pain domain)
✓ Support improvements in daily activity function (KOOS activities domain)
✓ Support improvements in sport and recreation performance (KOOS sport domain)
✓ Support joint-related quality of life over 6 months
✓ Be effective at a very low 40 mg daily dose
Why This Study Matters
These findings suggest that native type II collagen may help support joint comfort and mobility in individuals who place regular physical stress on their joints. This may be particularly relevant for recreational athletes, active adults, and individuals returning to exercise who are looking to maintain joint comfort and performance during physical activity. Supporting recovery and joint function may help individuals stay active and maintain consistent movement as part of a healthy lifestyle.*
Reference Link: https://pubmed.ncbi.nlm.nih.gov/36562843/
Study 2 Summary
Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/35612617/
Comparison Between Exercise Therapy and Non-Hydrolyzed Collagen (UC-II) in Functionality and Quality of Life in Women with Knee Osteoarthritis: A Randomized Controlled Clinical Trial
Wien Klin Wochenschr. 2023;135(11-12):291-300. doi:10.1007/s00508-022-02037-8. PMID: 35612617.
This randomized controlled clinical study evaluated the effects of 40 mg/day native (undenatured) type II collagen in 39 women experiencing knee joint discomfort. Participants were assigned to either a control group, a supplementation group, or an exercise intervention group and followed for six weeks. Researchers assessed joint function, mobility, and quality of life using WOMAC, knee range of motion measurements, and a six-minute walking test. Improvements observed in the collagen group were comparable to those seen in the exercise intervention group.
Study Design Highlights
- Study design: Randomized controlled clinical trial
- Participants: 39 women with knee joint discomfort
- Dose: 40 mg/day native type II collagen
- Duration: 6 weeks
- Comparison groups: Control, supplementation, and exercise intervention
Key Findings (What the Study Showed)
- WOMAC pain scores: 44.8% improvement compared to baseline
- Walking distance: 10.6% increase without discomfort
- Improvements in knee range of motion
- Improvements in overall joint function
- Results comparable to exercise intervention group
Benefits of Collavant® n2 Demonstrated by This Study
Based directly on the clinical outcomes, Collavant® n2 was shown to:
✓ Support a 44.8% improvement in WOMAC joint comfort scores
✓ Support a 10.6% increase in walking distance without discomfort
✓ Support improvements in knee range of motion
✓ Produce improvements comparable to an exercise intervention program
✓ Be effective at 40 mg/day over a 6-week period
Why This Study Matters
Supporting joint comfort and mobility can play an important role in maintaining daily activity and overall quality of life. The results of this study suggest that native type II collagen may help support comfortable movement and walking capacity in individuals experiencing joint stress. Maintaining joint mobility may help support everyday activities such as walking, climbing stairs, and staying physically active as part of a healthy lifestyle.*
Reference Link: https://pubmed.ncbi.nlm.nih.gov/35612617/
Study 3 Summary
Complete Study Information: https://www.ijoro.org/index.php/ijoro/article/view/1840
Efficacy and Safety of a Combination of Boswellia serrata Extract and Native Type II Collagen in Osteoarthritis: A Multicentric Clinical Study
Int J Otorhinolaryngol Head Neck Surg. 2020;6(9):1684–1690.
This multicentric observational clinical study evaluated a combination of native (undenatured) type II collagen (40 mg Collavant® n2) and Boswellia serrata extract (100 mg Aflapin®) in 40 adults experiencing knee joint discomfort across three clinical sites. Participants took one capsule daily for three months. Researchers evaluated joint comfort, stiffness, and physical function using VAS and WOMAC outcome measures.
Study Design Highlights
- Study design: Multicentric observational clinical study
- Participants: 40 adults experiencing knee joint discomfort across 3 clinical sites
- Dose: 40 mg native type II collagen + 100 mg Boswellia serrata extract (Aflapin®)
- Duration: 3 months
- Outcome measures: VAS and WOMAC scores for joint comfort, stiffness, and function
Key Findings (What the Study Showed)
- Improvements in VAS measures of joint discomfort
- Improvements in WOMAC measures of joint comfort, stiffness, and function
- Benefits observed as early as 5 days into supplementation
- Supplementation was well tolerated with no significant adverse events reported
Benefits of Collavant® n2 Demonstrated by This Study
Based directly on the clinical outcomes, the Collavant® n2 and Aflapin® combination was shown to:
✓ Support improvements in VAS joint comfort measures
✓ Support improvements in WOMAC joint comfort, stiffness, and function scores
✓ Produce measurable benefits as early as 5 days
✓ Demonstrate complementary effects when combined with Boswellia serrata
✓ Be well tolerated with no significant adverse events
Why This Study Matters
Supporting joint comfort and mobility is important for maintaining regular movement and daily activity. The results of this study suggest that combining native type II collagen with Boswellia serrata may help support comfortable movement and physical function in individuals experiencing joint stress — and the early 5-day onset suggests relatively rapid support for joint comfort.*
Reference Link: https://www.ijoro.org/index.php/ijoro/article/view/1840
Study 4 Summary
Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/27551171/
Effects of Native Type II Collagen Treatment on Knee Osteoarthritis: A Randomized Controlled Trial
Eurasian J Med. 2016;48(2):95-101. doi:10.5152/eurasianjmed.2015.15030. PMID: 27551171.
This randomized controlled clinical study evaluated the effects of adding 40 mg/day native (undenatured) type II collagen (Collavant® n2) to a standard joint care regimen in 39 adults experiencing knee joint discomfort. Participants were assigned to receive either acetaminophen alone (1,500 mg/day) or acetaminophen plus native type II collagen for three months. Outcomes were assessed using VAS, WOMAC, and SF-36 quality-of-life questionnaires, along with biomarkers associated with normal cartilage metabolism.
Study Design Highlights
- Study design: Randomized controlled clinical trial
- Participants: 39 adults experiencing knee joint discomfort
- Intervention:
- Control: 1,500 mg/day acetaminophen
- Active: 1,500 mg/day acetaminophen + 40 mg/day native type II collagen
- Duration: 3 months
- Outcome measures: VAS, WOMAC, SF-36, cartilage metabolism biomarkers
Key Findings (What the Study Showed)
- Greater improvements in VAS measures of joint comfort vs. standard regimen alone
- Improvements in WOMAC measures of joint function
- Improvements in SF-36 quality-of-life scores
- Favorable changes in biomarkers associated with normal cartilage metabolism
Benefits of Collavant® n2 Demonstrated by This Study
Based directly on the clinical outcomes, Collavant® n2 was shown to:
✓ Support greater improvements in joint comfort when added to a standard joint care regimen
✓ Support improvements in WOMAC joint function scores
✓ Support improvements in quality-of-life measures (SF-36)
✓ Support favorable changes in biomarkers associated with normal cartilage metabolism
✓ Complement standard joint care approaches at a low 40 mg daily dose
Why This Study Matters
Joint comfort plays an important role in maintaining mobility and everyday activity. The results of this study suggest that native type II collagen may help support joint comfort and functional movement in individuals experiencing joint stress, and that it may complement other joint support approaches. Supporting joint mobility may help individuals maintain normal daily activities such as walking, climbing stairs, and staying physically active.*
Reference Link: https://pubmed.ncbi.nlm.nih.gov/27551171/
Study 5 Summary
Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/19384621/
Biomarkers, Type II Collagen, Glucosamine and Chondroitin Sulfate in Osteoarthritis Follow-Up: The "Magenta Osteoarthritis Study"
J Orthop Traumatol. 2008;9(2):81–87. doi:10.1007/s10195-008-0007-5. PMID: 19384621.
This retrospective observational study evaluated the effects of adding native (undenatured) type II collagen to a glucosamine and chondroitin supplementation regimen in 104 adults experiencing joint discomfort affecting the hands, knees, or hips. Participants were followed for 12 months and divided into two groups: glucosamine and chondroitin alone (GC) vs. glucosamine, chondroitin, and native type II collagen (GCC). Researchers assessed joint comfort via VAS and examined biomarkers associated with normal cartilage turnover, including urinary CTX-I and CTX-II.
Study Design Highlights
- Study design: Retrospective observational study
- Participants: 104 adults experiencing joint discomfort (hands, knees, hips)
- Groups:
- GC: Glucosamine + Chondroitin (n=47)
- GCC: Glucosamine + Chondroitin + Native Type II Collagen (n=57)
- Duration: 12 months
- Outcome measures: VAS joint comfort scores; uCTX-I and uCTX-II cartilage metabolism biomarkers
Key Findings (What the Study Showed)
- Greater improvements in VAS measures of joint comfort in the GCC group vs. GC group
- Favorable changes in biomarkers associated with normal cartilage turnover (uCTX-I and uCTX-II)
- Improvements maintained at both 6- and 12-month assessments
Benefits of Collavant® n2 Demonstrated by This Study
Based directly on the clinical outcomes, adding native type II collagen to glucosamine and chondroitin was shown to:
✓ Support greater improvements in joint comfort over 12 months
✓ Support favorable changes in cartilage metabolism biomarkers (uCTX-I and uCTX-II)
✓ Demonstrate sustained benefits maintained at both 6 and 12 months
✓ Complement the effects of glucosamine and chondroitin for long-term joint support
Why This Study Matters
Maintaining joint comfort and mobility is important for supporting everyday movement and physical activity. The findings from this study suggest that combining native type II collagen with other commonly used joint support nutrients may help support long-term joint comfort and healthy cartilage metabolism in individuals experiencing ongoing joint stress. Supporting joint mobility may help individuals maintain normal activities such as walking, climbing stairs, and staying physically active.*
Reference Link: https://pubmed.ncbi.nlm.nih.gov/19384621/
Big-Picture Integration with Other Studies
- Study 1: In a 6-month randomized, placebo-controlled trial, 40 mg/day native type II collagen supported improved recovery from exercise-related joint discomfort and improvements in measures of joint function and quality of life in physically active adults.
- Study 2: In a 6-week randomized clinical trial in women experiencing knee joint discomfort, 40 mg/day native type II collagen was associated with a 44.8% improvement in WOMAC joint comfort scores and a 10.6% increase in walking distance, along with improvements in joint mobility.
- Study 3: In a 3-month multicentric observational study, supplementation with 40 mg native type II collagen combined with 100 mg Boswellia serrata extract supported improvements in joint comfort and physical function, with measurable improvements reported within the first week.
- Study 4: In a 3-month randomized controlled study, individuals receiving 40 mg/day native type II collagen alongside a standard joint care regimen demonstrated greater improvements in joint comfort, physical function, and quality-of-life measures compared to those receiving the standard regimen alone.
- Study 5: In a 12-month observational study of 104 adults experiencing joint discomfort, adding native type II collagen to a glucosamine and chondroitin regimen was associated with greater improvements in joint comfort and favorable changes in biomarkers related to normal cartilage metabolism.
Collavant® n2 Ingredient Summary & Real-World Relevance
Collectively, clinical and preclinical research suggests that Collavant® n2, a native (undenatured) type II collagen, may help support joint comfort, mobility, and cartilage health in individuals experiencing physical stress on the joints. Human clinical studies evaluating daily supplementation with 40 mg of native type II collagen have reported improvements in measures of joint comfort, functional movement, and mobility in both physically active individuals and populations experiencing joint discomfort. Unlike hydrolyzed collagen peptides that primarily serve as structural building blocks, native type II collagen functions through a mechanism known as oral tolerance, which helps support balanced immune responses associated with normal joint tissue and cartilage metabolism. Together, these findings suggest that Collavant® n2 may help support joint function, resilience, and comfortable movement as part of an active and healthy lifestyle.*
Ingredient Manufacturer Link: https://www.bioiberica.com/en/products/human-health/collavantr-n2
Collavant® n2 is a clinically studied ingredient used in the following Silver Fern™ Brand product:
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.